Clinical Features and Treatment Outcomes of Patients Infected with Novel Corona Virus 2019 in Wachemo University Nigist Eleni Mohamed Memorial Hospital

On 11 February 2020, the World Health Organization announced a new name for the epidemic disease caused by 2019-nCoV. Corona virus disease 2019 (COVID-19) is the third severe outbreak of a member of the corona vioridae family that has occurred during the past 20 years. The corona virus disease 19 (COVID-19) is a highly transmittable and pathogenic viral infection caused by severe acute respiratory syndrome. Corona virus is an envelope and single-stranded ribonucleic acid named for its solar corona-like appearance due to 9?12-nm-long surface spikes. Frontline workers including the health care workers were at increased risk of infection during the COVID-19 pandemic. Current management of COVID-19 is supportive, and respiratory failure from acute respiratory distress syndrome is the leading cause of mortality. The purpose of this study will be to assess clinical features and treatment outcomes of patients infected with novel corona virus. This study was applied health institution based quantitative studies with descriptive and analytic components to address its specific objectives. Target population for this study will be all confirmed COVID-19 patients who are treatedat Nigist Eleni Mohamed memorial hospital. All confirmed covid 19 patients who were admitted at the treatment center of Nigist Eleni hospital was included in this study. Result: Three fourth (75%) of the COVID-19 patients admitted to Wachemo university Nigist Eleni hospital was male, followed by older aged patients greater than 65 (22.5%). More than half of the patients were admitted in March and April (59.2%). Two patients out of 120 were pregnant. In March and April there are the highest number of patients admitted to the covid centre.Forty-three percent of the patients is having one or more comorbidities. From the patients having comorbidities 25 (50%) patients were hypertensive followed by diabetes mellitus 21 (40%).